Filing Flows › 8-K events › Charles River Laboratories International
Charles River Laboratories International: regulation fd disclosure
Form 8-K filed Nov 9, 2026 · items 7.01
Mergers and acquisitionsCHARLES RIVER LABORATORIES TO ACQUIRE
What the filing says
– Strengthens Charles River's Bioanalysis and DMPK Capabilities to Support Clients Across the Drug Development Lifecycle –
Read the filing on SEC EDGAR →
Charles River Laboratories International at a glance
Latest quarterQ3 2026
Revenue$982.7M
Revenue Y/Y-2%
Operating margin20.6%
IndustryServices-Commercial Physical & Biological Research
Charles River Laboratories International, Q3 2026: revenue $983M (-2% year over year), operating margin 20.6%. The chart follows the revenue to costs, profit and cash.
Charles River Laboratories International: every quarter, Q/Q and Y/Y, holders and guidance →
Other recent mergers and acquisitions
- loanDepot Nov 9, 2026
- Somnigroup International Nov 9, 2026
- Starry Sea Acquisition Nov 6, 2026
- Kontoor Brands Nov 6, 2026
- Terawulf Nov 6, 2026
- Plains GP Holdings LP Nov 6, 2026
- Pono Capital Four Nov 6, 2026
- HeartSciences Nov 6, 2026
- Agility Robotics Nov 6, 2026
- Crown PropTech Acquisitions Nov 6, 2026
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.